Trial · NCT00429416
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Diarrhea | General disorders | LLME to Decrease GVHD Following HSC T | 2 | 14 | 2 |
| serious | Bone marrow cellularity | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Infection | General disorders | LLME to Decrease GVHD Following HSC T | 3 | 14 | 7 |
| serious | Pancyptopenia | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Hematoma | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Death | General disorders | LLME to Decrease GVHD Following HSC T | 7 | 14 | 7 |
| serious | Hypersensitivity | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Chest pain | General disorders | LLME to Decrease GVHD Following HSC T | 2 | 14 | 2 |
| serious | Progressive disease | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Nausea | General disorders | LLME to Decrease GVHD Following HSC T | 3 | 14 | 3 |
| serious | Vomiting | General disorders | LLME to Decrease GVHD Following HSC T | 2 | 14 | 2 |
| serious | Fevers | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Rash | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Prostatic obstruction | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Pericardial effusion | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Opportunistic infection | General disorders | LLME to Decrease GVHD Following HSC T | 3 | 14 | 3 |
| serious | Bladder obstruction | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 2 |
| serious | Hepatic failure | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Renal insufficiency | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
| serious | Renal failure | General disorders | LLME to Decrease GVHD Following HSC T | 1 | 14 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00429416/events